Monday, April 6, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Congress questions medical device manufacturers on opioid settlement tax breaks

Four pharmaceutical companies in settlement talks with states to resolve claims related to their involvement in the national opioid crisis stand to reap about $1 billion each in tax breaks if a combined payout of more than $26 billion is finalized, according to company filings.

The drug distributors McKesson Corp. , AmerisourceBergen Corp. and Cardinal Health Inc., along with Johnson & Johnson , plan to deduct the payouts from their taxes, filings show.

Cardinal, which expects to pay $6.6 billion as part of the settlement, said in a regulatory filing earlier this month that it anticipates receiving a $943 million tax benefit as a result of losses it incurred because of the payout charge. The company said it has filed for an income tax refund it expects to receive in the next 12 months.

Cardinal, based in Dublin, Ohio, said $420 million of the benefit would come from offsetting profits from prior tax years when there was a higher corporate income-tax rate, taking advantage of a provision created by Congress as part of its Covid-19 economic-relief package last March

Source: Wall Street Journal

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

Semaglutide and the Expansion Problem: When One Trial Becomes a Platform

Semaglutide and the Expansion Problem: When One Trial Becomes a Platform

Semaglutide has moved beyond its original indication and now sits at the center of a widening set of clinical questions: cardiovascular risk, kidney disease progression, and even neurodegeneration. The question is no longer whether the drug lowers glucose or reduces weight—it does—but how far those effects extend across systems, and whether evidence from one population can be translated into another without distortion. Large, well-powered trials have produced consistent signals, yet those signals are now being applied in contexts that were...

Read more

Join Our Newsletter!